Incidence and Associated Factors of Schneiderian Membrane Perforation in Maxillary Sinus Floor Elevation: A Meta-Analysis.

Int Dent JJul 23, 2026 (epub)
Clinical ResearchOtolaryngology (ENT)General SurgeryOpen access

Yanmei Liu, Qiuyu Zhou, Enhong Li et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis examined the incidence and factors associated with Schneiderian membrane perforation (SMP) during maxillary sinus floor elevation (MSFE) in 4519 patients across 26 studies. The pooled incidence of SMP was found to be 0.19 per patient and per surgery. Significant associations were identified with sinus septa and smoking.

Key findings

  • The pooled incidence of SMP was 0.19 per patient and per surgery.
  • Sinus septa were associated with higher odds of perforation (OR = 3.56).
  • Smoking increased the odds of perforation (OR = 2.57).
  • No significant effects were found for other prespecified factors.

Why it matters

Understanding the incidence and associated factors of SMP can enhance preoperative assessments and surgical planning, ultimately improving patient outcomes during MSFE procedures.

Source

PubMed · PMID 42492462Free full text on PubMed Central

Published in Int Dent J. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Otolaryngology (ENT)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.